BIBLIOGRAPHIE : Cannabinoïdes, Dépression et Troubles de l’Humeur Docteur Christian SUEUR, GRECC, novembre 2019.
Lire la suiteCannabinoids, Neurogenesis and Antidepressant Drugs : Is there a Link ? Manoela Viar Fogaça, Ismael Galve-Roperh, Francisco Silveira Guimarães and Alline Cristina Campos Current Neuropharmacology, 2013, 11, 263-275 Abstract Similar to clinically used antidepressants, cannabinoids can also regulate anxiety and depressive symptoms. Although the mechanisms of these effects are not completely understood, recent evidence suggests that changes in endocannabinoid system could be involved in some actions of antidepressants. Chronic antidepressant treatment modifies the expression of CB1 receptors and endocannabinoid (EC) content in brain regions related to mood and anxiety control. Moreover, both antidepressant and cannabinoids activate mitogen-activated protein (MAP) kinase and phosphoinositide 3- kinase(PI3 [...]
Lire la suiteBipolar disorder and the endocannabinoid system Shokouh Arjmand, Mina Behzadi, Kristi A. Kohlmeier, Shahrzad Mazhari, Abdolreza Sabahi and Mohammad Shabani Acta Neuropsychiatrica, 2019, 1-9. https://doi.org/10.1017/neu.2019.21 Abstract Objective : Bipolar disorder (BD) is a debilitating, lifelong neuropsychiatric illness characterised by unsteady mood states which vacillate from (hypo)mania to depression. Despite the availability of pharmaceutical agents which can be effective in ameliorating the acute affective symptoms and prevent episodic relapse, BD is inadequately treated in a subset of patients. The endocannabinoid system (ECS) is known to exert neuromodulatory effects on other neurotransmitter systems critical in governing emotions. Several studies ranging from clinical to molecular, as well as [...]
Lire la suite2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity Leanne Lu, Gareth Williams, and Patrick Doherty Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2019.0030 Abstract Introduction : The cannabinoid type 1 (CB1) receptor and cannabinoid type 2 (CB2) receptor are widely expressed in the body and anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are their best characterized endogenous ligands. The diacylglycerol lipases (diacylglycerol lipase alpha and diacyl-glycerol lipase beta) not only synthesize essentially all the 2-AG in the body but also generate other monoacylglycerols, including 2-linoleoylglycerol (2-LG). This lipid has been proposed to modulate endocannabinoid [...]
Lire la suiteThe endocannabinoid system : an overview Natalia Battista, Monia Di Tommaso, Monica Bari and Mauro Maccarrone Frontiers in Behavioral Neuroscience, 2012|Volume 6|Article 9 | 1 doi: 10.3389/fnbeh.2012.00009 Upon the identification of anandamide (AEA) in the porcine brain, numerous studies contributed to the current state of knowledge regarding all elements that form the “endocannabinoidsystem (ECS).” How this complex system of receptors, ligands, and enzymes is integrated in helping to regulate fundamental processes at level of central nervous and peripheral systems and how its regulation and dysregulation might counteract disturbances of such functions, is now a days still under investigation. However, the most recent advances on [...]
Lire la suiteClinicians’ Guide to Cannabidiol and Hemp Oils Harrison J. VanDolah, Brent A. Bauer, and Karen F. Mauck Mayo Clinic Proceedings, 2019, 94, (9), 1840-1851 https://doi.org/10.1016/j.mayocp.2019.01.003 Abstract Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and [...]
Lire la suiteEndocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies Matthew E. Sloan, Caroline W. Grant, Joshua L. Gowin, Vijay A. Ramchandani and Bernard Le Foll Acta Pharmacologica Sinica, 2018, 0, 1–9; https://doi.org/10.1038/s41401-018-0081-z Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric [...]
Lire la suiteCannabis Withdrawal Nicolas J. Schlienz and Ryan Vandrey I. D. Montoya, S. R. B. Weiss (eds.), Cannabis Use Disorders, https://doi.org/10.1007/978-3-319-90365-1_11 Introduction Drug withdrawal refers to a constellation of symptoms that occur following abrupt cessation of chronic drug use. Though drug withdrawal can occur from stopping use of medication, it is most often encountered within the context of illicit, non-medicinal, drug use. The withdrawal symptoms that emerge following extended and frequent use of abused drugs are a key feature of what define substance use disorders [4, 85]. Further, there is accumulating neurobiological evidence that withdrawal drives the maintenance of problematic substance misuse through a mechanism of [...]
Lire la suiteThe Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]
Lire la suiteAnandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]
Lire la suite